-
公开(公告)号：EP1940447B1
公开(公告)日：2013-11-27
申请号：EP06793581.7
申请日：2006-09-18
CPC分类号： A61K38/1816 , A61K47/60
-
2.发明公开COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1 审中-公开KOMBINATIONSTHERAPIE MIT抗生素GEGEN人类CSF-1R抗原抗体GEGEN人类PD-L1
公开(公告)号：EP3044235A1
公开(公告)日：2016-07-20
申请号：EP14761904.3
申请日：2014-09-11
发明人： HERTING, Frank , RIES, Carola , WARTHA, Katharina , HOVES, Sabine
摘要： The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1.
摘要翻译： 本发明涉及将人CSF-1R与结合人PD-L1的特异性抗体结合的特异性抗体的组合治疗。
-
3.发明公开
公开(公告)号：EP1778683A1
公开(公告)日：2007-05-02
申请号：EP05748028.7
申请日：2005-06-13
发明人： FERTIG, Georg , HERTING, Frank , KOERNER, Matthias , KUBBIES, Manfred , LIMBERG, Anja , REIFF, Ulrike , TIBES, Ulrich
IPC分类号： C07D413/12 , C07D333/44 , C07D333/58 , C07D409/12 , C07D413/14 , C07D409/14 , A61K31/422 , A61K31/381 , A61K31/4155 , A61K31/404 , A61K31/4436 , A61K31/4178 , A61P35/00
CPC分类号： C07D409/12 , C07D333/44 , C07D333/58 , C07D409/14 , C07D413/12 , C07D413/14
摘要： Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
-
4.发明公开THIOPHENE HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HDAC INHIBITORS 审中-公开噻吩异羟肟酸衍生物及其作为HDAC抑制剂的用途
公开(公告)号：EP1758881A1
公开(公告)日：2007-03-07
申请号：EP05776155.3
申请日：2005-06-13
发明人： FERTIG, Georg , HERTING, Frank , KOERNER, Matthias , KUBBIES, Manfred , LIMBERG, Anja , REIFF, Ulrike , TIBES, Ulrich
IPC分类号： C07D333/38 , A61K31/381 , A61P35/00
CPC分类号： C07D333/38
摘要： Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明的目的是式（I）化合物，其药学上可接受的盐，对映体形式，非对映异构体和外消旋体，上述化合物的制备，含有它们的药物及其制备，以及上述药物的用途， 上述化合物用于控制或预防诸如癌症的疾病。
-
公开(公告)号：EP1758880A1
公开(公告)日：2007-03-07
申请号：EP05750667.7
申请日：2005-06-13
发明人： FERTIG, Georg , HERTING, Frank , KOERNER, Matthias , KUBBIES, Manfred , LIMBERG, Anja , REIFF, Ulrike , TIBES, Ulrich
IPC分类号： C07D333/38 , A61K31/381 , A61P35/00
CPC分类号： C07D333/38
摘要： Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
-
公开(公告)号：EP1940447A1
公开(公告)日：2008-07-09
申请号：EP06793581.7
申请日：2006-09-18
CPC分类号： A61K38/1816 , A61K47/60
摘要： The invention relates to the use of an erythropoietic molecule for the production of a medicament for the treatment of neurodegenerative disorders of the brain and the spinal cord by administering an effective amount of the medicament in the blood circuit of a patient in need of such therapy wherein the erythropoietic molecule comprises an erythropoietin moiety having at least one free amino group selected from the group consisting of human erythropoietin and analogues thereof which have the sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said erythropoietin moiety being covalently linked to 'n' poly(ethylene glycol) groups of the formula -CO-(CH2)x- (OCH2CH2)m-OR; and a kit comprising an erythropoietic molecule according to the invention.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.012 秒)
